Related Experiment Video

Updated: Mar 15, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

[Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report]

Sai-Nan Pi1, You-Peng Chen

  • 1Department of Infectious Diseases, First Affiliated Hospital of Jinan University, Guangzhou 510630, China.

Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University
|September 1, 2016
PubMed

Insights

Daclatasvir and asunaprevir combination therapy achieved a sustained viral response in a Chinese patient with chronic hepatitis C genotype 1b. This treatment led to a clinical cure, demonstrating its efficacy in this population.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) genotype 1b is a significant global health concern.
  • Daclatasvir and asunaprevir combination therapy has shown efficacy in HCV genotype 1 treatment.
  • Limited data exists on this regimen for Chinese patients with chronic hepatitis C (CHC) genotype 1b.

Observation:

  • A 44-year-old Chinese female patient with CHC genotype 1b was treated with daclatasvir and asunaprevir for 24 weeks.
  • The patient experienced transient hyperbilirubinemia and mild anemia during therapy.
  • Hemoglobin levels fluctuated between 100 and 110 g/L.

Findings:

  • The patient achieved a sustained viral response (SVR) post-treatment.
  • Clinical cure was observed after the 24-week treatment course.
  • The regimen was effective despite transient laboratory abnormalities.

Implications:

  • This case suggests daclatasvir and asunaprevir is a viable treatment option for Chinese CHC genotype 1b patients.
  • Further research is warranted to confirm efficacy and safety in larger cohorts.
  • This regimen offers a potential therapeutic strategy for HCV genotype 1b in diverse populations.
Abstract

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.4K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
456
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
842